This article explores key questions on how Medical Affairs teams manage patient engagement across different-sized companies who have variations in focus, resources, and scale.
Regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly recognising the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting.
Consequently, Pharma companies are increasingly including real-world studies in their evidence to:
• Understand the opportunities and best practices for involving patient partners in the generation of real-world evidence
• Explore, using case studies, the value of patient engagement in the design, delivery, analysis and communication of real-world studies
• Highlight the importance of Medical Affairs and Health Economics and Outcomes Research (HEOR) professionals in partnering with colleagues from different functions in Pharma to ensure patients are effectively engaged throughout the product lifecycle
• Discuss barriers and propose solutions to optimal patient engagement in real-world studies
Getting the most impact from a publication requires being able to define who the audience is and how to reach them, across both journals and online channels, especially in complex/niche cases. In this podcast, we discuss the benefits of taking an analytical approach.
By the end of this webinar, attendees should...
1. Be able to articulate why it’s important to consider a patient community audience when planning scientific and data dissemination including incorporating their voice within it.
2. Be confident to follow clear methodologies to incorporate the patient voice within publications and the role of Medical Affairs in disease awareness campaigns.
3. Be able to implement best practice approaches including novel ways to disseminate information.
This e-Learning module will enable learners to define principles of and adopt an integrated approach to orchestrating omnichannel Company-led Education, identify stakeholder segmentation and associated learning journeys for use in content development, use the associated outcomes and insights to deliver and improve omnichannel medical education, while complying with industry regulations as well as company governance and oversight policies.
This webinar will focus on the role of Medical Affairs to lead patient engagement in clinical development.
Health literacy is experiencing new challenges, and Medical Affairs is uniquely positioned to lead and partner with others in this space to ensure coordination, credibility and impact.
MAPS speaks with Liz de Somer, CEO of Medicines Australia and Sharon Winton, CEO of Lymphoma Australia to explore patient engagement from the perspectives of industry and patient associations.
The MAPS Patient Centricity FAWG surveyed Medical Affairs community, including MAPS members, for their input on patient centricity initiatives within their respective organizations. We will be sharing insights from the recent MAPS Patient Centricity Survey on industry perspectives, including the major barriers to implementing initiatives that were identified in the survey. Our experts will be providing guidance and potential solutions on addressing major barriers for patient centricity initiatives identified through the survey.
This session will 1) Discuss why patient inclusion is important for Medical Affairs Professionals 2) Look at processes and potential barriers to inclusion of the patient perspective in Medical Affairs deliverables and development of clinical trial protocols; 3) Provide you with the resources to successfully establish a compliant process for patient engagement; and 4) will ultimately provide insights on how to work with patients in a compliant manner.